Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

Time in range metrics were similar, if not better, among older vs younger adults with T1D using automated insulin delivery systems.

Truist lowered the firm’s price target on Medtronic (MDT) to $90 from $93 and keeps a Hold rating on the shares as part of a broad research ...

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.